There is consistent experimental evidence that the extracellular matrix remodeling, antiangiogenic and antiproliferative effects mediated by non-tumoral SPARC, produced by stromal fibroblasts or endothelial or hematopoietic cells, constitutes a barrier to tumor progression, invasion and metastasis in mouse models of lung, ovarian, bladder, prostate or pancreas cancers [43, 46–50]. Here, SPARC is linked to neoplasm.